A randomized controlled trial demonstrates that smokers with a 'sign-tracker' neuroaffective profile achieve significantly higher abstinence rates with varenicline compared to nicotine replacement therapy, supporting biomarker-guided prescribing for smoking cessation.
A double-blind RCT demonstrates that neurobiomarker-guided repetitive transcranial magnetic stimulation (rTMS) yields greater depressive symptom improvement than sham in youth with major depressive episodes, supporting precision neuromodulation strategies.
Qualitative data from an open-label pilot suggest ketamine-assisted psychotherapy creates 'psychological space' that facilitates engagement in treatment for methamphetamine use disorder, though sustained behavioral change remains variable.
This case report demonstrates that religious OCD responds comparably to standard OCD subtypes with optimized SSRI monotherapy or augmentation, challenging the notion of inherently poorer treatment outcomes.
A 12-month naturalistic study found that while both men and women with schizophrenia showed significant improvements on cariprazine, distinct gender-specific response profiles emerged across symptom domains.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Jun 22 – Jun 24)
- Consider ketamine infusions as a rapid-acting option for acute major depressive episodes, given the confirmed efficacy in recent meta-analyses.
- Utilize varenicline over nicotine replacement therapy for smokers identified with a 'sign-tracker' neuroaffective profile to maximize abstinence rates.
- Optimized SSRI monotherapy or augmentation can be effective for religious OCD, countering the assumption that this subtype has inherently poorer treatment outcomes.
- Monitor for gender-specific response profiles when prescribing cariprazine for schizophrenia, as symptom domain improvements may differ between men and women over a 12-month period.
- Evaluate neurobiomarker-guided rTMS for youth with major depressive episodes to potentially achieve greater symptom improvement compared to standard sham protocols.
- Explore ketamine-assisted psychotherapy as an adjunctive strategy for methamphetamine use disorder to create psychological space that facilitates engagement in treatment.
- Engage with the FDA regarding the future development of ML-004 for autism, noting its recent Phase 2 trial failure to meet primary endpoints.
- Keep emerging genomic findings on schizophrenia risk genes in mind as they may inform future precision medicine approaches and target identification.
Diagnosis & Treatment 1
A meta-analysis published in JAMA Psychiatry confirms that ketamine infusions rapidly reduce symptoms of major depressive episodes during the acute phase.
Neuroscience 1
A large-scale genomic study identified 641 novel risk genes for schizophrenia through network mapping, potentially informing future precision medicine approaches.
Drug Development 1
MapLight Therapeutics' Phase 2 trial for its autism drug ML-004 failed to meet its primary endpoint, prompting discussions with the FDA regarding the drug's future development.